Science Investors - SAG

Science Investors - SAG

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Science Group Plc SAG London Ordinary Share GB00B39GTJ17 ORD 1P
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 345.00 07:43:59
Open Price Low Price High Price Close Price Previous Close
345.00 345.00 345.00 345.00 345.00
more quote information »
Industry Sector
SUPPORT SERVICES

Top Investor Posts

DateSubject
06/11/2020
09:28
hazl: Headline 12/10/2020 11:21 ALNC Science Group Anticipates 2020 Profit Ahead Of Expectations 12/10/2020 06:00 UKREG Science Group PLC Trading Update 08/10/2020 06:00 UKREG Science Group PLC Issue of share options & PDMR dealing 05/10/2020 06:00 UKREG Science Group PLC TR1: Notification of Major Interest in Shares 01/10/2020 10:15 UKREG Science Group PLC TR1: Notification of Major Interest in Shares 30/09/2020 14:59 ALNC UK DIRECTOR DEALINGS SUMMARY: Science Group Chair Sells 4.8% Stake 30/09/2020 13:30 UKREG Science Group PLC Director Dealing & Exercise of Share Options With Headlines like this I tend to agree.
04/3/2015
08:08
battlebus2: Still a clear under valuation imv.. I also believe it's likely we will see a new institutional investor.
04/3/2015
07:56
battlebus2: Results out. As expected with the difficult currency headwinds. Second half back to growth. Cash balances worth 86p 4P dividend and a buy back of up to 10% of the shares in issue, this may be used to facilitate an institutional investor to gain a holding due to lack of liquidity at present Still on the look out for acquisitions. Summary In summary, 2014 had a more challenging start than the prior year which, as previously reported, had been exceptionally strong. This was made more difficult by a rapidly deteriorating foreign exchange environment in the first half. However the second half of the year saw a return to organic growth in the core consultancy business, despite the negative currency impact. Through tight cost control, operating margins were above the Board's target and a satisfactory overall result for the year was achieved. The integration of OTM Consulting, acquired in mid-2013, has been successful and the integration of Oakland is now in progress. The Board continues to evaluate corporate opportunities to accelerate the growth of Sagentia, although there can be no certainty that any transaction(s) will occur. In the absence of a major acquisition, the Board has considered how best to deliver value for Shareholders and is proposing specific measures, namely a very attractive dividend, increased share buy-back programme and supply side liquidity. Shareholders will have the opportunity to vote on these proposals at the Annual General Meeting, scheduled for 21 May 2015.
18/2/2015
12:34
battlebus2: Great to see another tick up, mustn't be far from some news imv.. 17 February 2015 We recently attended the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. This month, Sagentia’s VP of Surgical, Alistair Fleming, reflects on some of the major themes and topics highlighted during the event. Perhaps unsurprisingly, data proved to be a frequent talking point at this year’s conference, with ‘information liquidity’ being a key theme, but what does this phrase mean? In the past, a lack of data stood in the way of better care. Now the opposite is true: healthcare is inundated with data. We have electronic patient records, tracking data on patient condition, co-morbidities and changes in scientific flow to give just a few examples. With this new wealth of data the healthcare industry is witnessing the emergence of an array of new services. These services are designed to enable ‘information liquidity’: streamline workflow, make data seamlessly available anywhere and at any time through easy but secure, sharing and storage. One example offered at the conference focused around the area of Bioinformatics. Illumina’s BaseSpace, which has been developing over the past few years and is touted as the world’s largest genomics cloud with 125,000 runs of customer test data is a cloud computing environment for next-generation sequencing (NGS) data analysis and management. BaseSpace is designed to be flexible, available in both cloud and onsite solutions. The aim is to allow sequencing labs to easily and securely analyse, archive, and share sequencing data. Researchers can then simplify and accelerate NGS data analysis with push-button tools. BaseSpace is gathering interest from both customers and collaborators, but there are still many developments planned for the system and, as healthcare data services advance, we expect the field of Bioinformatics to receive increasing attention at investor updates over the next couple of years. The opportunities for liquid biopsies – non-invasive blood tests for tumour diagnosis – and the recent advancements in genetic sequencing and molecular diagnosis, were also highlighted during the week’s proceedings. It is now possible to learn a great deal about what is occurring in a person’s body by testing a blood sample, a significantly less invasive method of investigation. While developments in the non-invasive pre-natal diagnostic market are well documented (including our client Premaitha), the applications for this approach in oncology are truly exciting and could transform clinical practice. Indicative signs in a sample of blood may help physicians detect cancerous tumours located elsewhere in the body. The current methods rely upon symptomatic presentation and imaging followed by tissue biopsies, which are costly, invasive and by definition only pick up a relatively progressed disease state. Liquid biopsies would minimise the need for hospital admissions and biopsy surgery for the patient, and could also enable more early-stage diagnosis, potentially to be carried out at home. Finally, with the increased IPO and M&A activity experienced in 2014, attendees at the conference were bolstered by the news that confidence has returned and investors expect 2015 to see even higher levels of activity in these areas. The recent merger between Covidien and Medtronic was still causing a buzz and demonstrates the possibilities that such synergies can bring to the whole care pathway. For example, companies might provide products for use by surgeons in the operating room, as well as supplying services to patients post-operatively. Through the pooling of resources, this situation offers the potential to spread costs among all of the suppliers in the care pathway. More intriguingly however, the combined group has the ability to redistribute cost and associate value derived at one stage in the care pathway with cost incurred elsewhere. This could have significant benefit for both suppliers and patients. Cost efficiencies would be achieved by the suppliers, which could then be passed on to patients in the form of improved procedures and outcomes. In all, it feels like 2015 starts with much promise and buzz in the industry. New technologies are driving innovation not just in products, but in services and business models in ways that could fundamentally transform the industry in coming years. Given the pressures on healthcare provision, this is welcome news.
27/3/2014
12:59
truffle: You're probably not missing anything. Its a good company, run by an excellent Chairman, and making consistently steady progress so it would seem. Check the past 3/4 years growth. However, it seems to remain under the radar of most investors so not much BB activity, but that's not necessarily a bad thing.
06/3/2012
13:55
abadan2: Not sure if anyone has pointed this out but, if you sell shares in the tender, this is taxed as a capital gain (and some investors will have losses to offset against the profits) while a dividend is taxed as income, so certianly better for higher rate tax payers. Clearly, the 80p price is designed to ensure that eps improve as a consequence.
05/3/2012
11:07
thepopeofchillitown: Some very shortsighted investors here. Fundementals still strong. £2.5m profit versus £20m Mark Cap. Undervalued. Longer term this will be above £1.
05/3/2012
10:11
greenroom78: By 'support' I mean why would you sell for less than 80p when management are offering you 80p to buy them back from you? Currently they are offering to take on almost 25% of the shares in issue at that price. Essentially I see it as a share buyback at a fixed price, I do wonder if an II (or large investor) has leant on management to do something like this to give them an opportunity to exit.
05/3/2012
09:19
greenroom78: The tender offer does provide support to the current price and 'should' underpin the price at these levels. It 'should' provide confidence to PI's and new investors that the price will remain supported at 80p but does not provide a return unless they sell their holding. A dividend of 15-20p would've given a return but most likely at the expense of a drop in capital value, I guess the other option would've been to introduce an annual dividend with a decent yield of 5% and make it clear that while cash is strong the dividend will be progressive. IMO The 80p should not be seen as what the company values itself at, more of an opportunity for large holders to sell in size. I guess the way to look at it is if you want to sell in size it would either take a long time or crash the market so this does provide liquidity for those otherwise locked into their holding. The 80p offer is not really for PIs unless they have a large holding.
12/12/2011
18:17
cfro: 'tis a very funny time of the day to release a trading statement. Why no share price reaction? Well, apart from a lot of investors missing it, i would say the word 'slightly' ahead instead of 'significantly' ahead perhaps has disappointed some. If its only going to be the 'slighty' ahead then slightly ahead of what?....7.4p ??......then if so can we expect 8p eps? But nevertheless, even suggestiong eps of 8p would still put the share price on a PE of 11 which is still too cheap imo. What interests me most tho, is all that cash. The co could pay us shareholders out say, 10% of that and still retain a decent amount.
ADVFN Advertorial
Your Recent History
LSE
SAG
Science
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210516 18:26:49